Just as the US cell-based immunotherapy company Juno Therapeutics was suspended and released by the FDA because of clinical trial failures, multinational pharmaceutical giants including Merck and GE Healthcare are well positioned in the field of biotherapy.
On July 13, a spokesman for the pharmaceutical giant Merck confirmed a new notice of layoffs to foreign media such as Fortune, which is said to be aimed at faster exploration of the biological field.
“The company will make some internal organizational adjustments in the areas of development, preclinical, early development, etc. At present, we are unable to provide a list of changes, or the number of employees affected, but we expect that about 10% of research, clinical, and early R&D colleagues will receive Impact." Information from this notice shows.
This means that as personnel and resources adjust to Kenilworth and Rahway in New Jersey, approximately 300 staff members in North Wales, Pennsylvania, may be laid off or transferred, and the layoffs are only 3 times from the last layoff of 8,500 employees. year. The purpose of the layoffs at that time was to save more money for research and trading, reflecting the new strategy of Merck's reform of the R&D department.
In fact, since acting in 2011, Merck's CEO Ken Fraser has been working on the simplification of the company's business. Since the company's restructuring plan in 2010, the number of layoffs has been rising. In 2015, the statistics showed that the pharmaceutical company had cut down no more than 36,000 jobs in five years.
However, while Merck closed a door, it opened another window. The spokesman said that the latest round of layoffs highlights Merck's determination to move to the field of bio-exploration. Merck will also establish new laboratories in Massachusetts and California.
Masai’s new laboratory in Saskatchewan will “focus on emerging sciences and unknown medical fieldsâ€. Initial exploratory research will include host-pathogen interactions, the role of microorganisms in disease progression, and more. The research station is scheduled to open at the end of this year. There will also be a new experimental center in the San Francisco Bay Area, with a temporary agency expected to be established in early 2017 to recruit 100 scientists. It will focus on cancer immunotherapy, cardiovascular and metabolic diseases.
In addition, Merck has been hoping to integrate services such as tumors, data transmission, and biologics into a comprehensive research station. This research station is now in the final stage. Merck said its Palo Alto research station will continue to focus on the discovery of immuno-oncology and biologics, vaccines, etc. before the establishment and operation of the integrated research station.
We have existing disposable masks, we insist on the design, multiple protections, multiple filters, and breathe well. Break the single, a variety of colors for you to choose, make your world full of color and vitality, skin-friendly, breathable, strict protection, comfortable fabrics fit the zipper cloth, long-wearing is not stuffy. The super-elastic hanging ear rope adopts super-elastic bubble rope, which is comfortable and skin-friendly for a long time, and relaxes all day long. The quality is guaranteed, and the multi-layer high-quality meltblown cloth keeps you away from outside intrusions in your life, and the effective blocking rate is high. The unique streamline cut, simplify the facial curve, skin-friendly and comfortable, no lipstick, no makeup. Breathable non-woven fabric, flannel filter layer, skin-friendly and non-irritating. We are the supplier and manufacturer of China's anti-dust masks, disposable anti-dust masks, providing low-price, high-quality earmuffs masks, ordinary disposable masks, etc.
Dust Mask,Disposable Dust Mask,Ear-Loop Mouth Mask,Ordinary Disposable Mask
KUTA TECHNOLOGY INDUSTRY CO.,LIMITED , https://www.kutasureblue.com